The evolving role of maintenance therapy using epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in the management of advanced non-small-cell lung cancer

Clinical Medicine Insights: Oncology

Volumn 6, Issue , 2012, Pages 137-147

  Huang, Chao H ^a,b   Powers, Benjamin C ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

EGFR TKI; Lung cancer maintenance

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; GEFITINIB; GEMCITABINE; PACLITAXEL; PEMETREXED; PLACEBO;

CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL STUDY; DIARRHEA; DRUG ERUPTION; DRUG MECHANISM; DRUG METABOLISM; HUMAN; LUNG NON SMALL CELL CANCER; MAINTENANCE CHEMOTHERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE;

EID: 84859708643     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S5127     Document Type: Review

References (50)

1. American Cancer Society Facts and Figures 2011.
2. http://www.nationallungcancerpartnership.org/lung-cancer-info/lung-cancer-research/url/e-link. Accessed October 10, 2011.
3. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355: 2542-50.
4. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomized phase III trial. Lancet. 2009;373:1525-31.
5. Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatingemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomized phase III trial (AVAIL). Ann Oncol. 2010;21:1804-9.
6. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cispltin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543-51.
7. Lara PN Jr, Redman MW, Kelly K, et al. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol. 2008; 26:463-7.
8. Park JO, Kim SW, Ahn JS, et al. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum- based chemotherapy in non-small-cell lung cancer. J Clin Oncol. 2007;25:5233-9.
9. Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by secondline therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol.2002;20:1335-43.
10. Barata F, Parente B, Teixeira E, et al. Optimal duration of chemotherapy in non-small-cell lung cancer: multicenter, randomized, prospective clinical trial comparing 4 vs. 6 cycles of carboplatin and gemcitabine. J Thorac Oncol. 2007;2:S666.
11. Smith IE, O'Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol. 2001;19: 1336-43.
12. von Plessen C, Bergman B, Andresen O, et al. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer. 2006;95:966-73.
13. Kris MG, Natale RB, Herbst RS, et al. Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer. JAMA. 2003;290:2149-58.
14. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366:1527-37.
15. Cohen MH, Williams GA, Sridhara R, et al. Report from the FDA: United States Food and Drug Administration Drug Approval Summary: Gefitinib (ZD1839; Iressa) Tablets. Clin Cancer Res. 2004;10: 1212-8.
16. Sheperd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in Previously Treated Non-Small-Cell Lung Cancer. N Engl J Med. 2005;353:123-32.
17. Lynch TJ, Bell DW, Sordella R, et al. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small- Cell Lung Cancer to Gefitinib. N Engl J Med. 2004;350:2129-39.
18. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304: 1497-500.
19. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19:183-232.
20. Hamilton M, Wolf JL, Rusk J, et al. Effects of Smoking on the Pharmacokinetics of Erlotinib. Clin Cancer Res. 2006;12:2166-71.
21. http://www.gene.com/gene/products/information/pdf/tarceva-prescribing. pdf. Accessed March 11, 2011.
22. Socinski MA, Morris DE, Masters GA, et al. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest. 2003;123:226S-43.
23. Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: Quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group study BR.21. J Clin Oncol. 2006;25:3831-7.
24. Goldie JH, Coldman AJ, Gudauskas GA. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep. 1982;66:439-49.
25. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in Combination with Gemcitabine and Cisplatin in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial-INTACT 1. J Clin Oncol. 2004;22:777-84.
26. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol.2004;22:785-94.
27. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined with Carboplatin and Paclitaxel Chemotherapy in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2005;23:5892-9.
28. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non-Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007;25:1545-52.
29. Tudor Ciuleanu, Thomas Brodowicz, Christoph Zielinski, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. The Lancet. October 24-30, 2009; 374(9699):1432-40.
30. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomized, placebo-controlled phase 3 study. Lancet Oncol. 2010;11:521-9.
31. Cella D, Bonomi A, Lloyd S, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer. 1995;12:199-200.
32. Kabbinavar FF, Miller VA, Johnson BE, et al. Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-smallcell lung cancer (NSCLC). J Clin Oncol. 2010;28 Suppl:Abstr 7526.
33. Perol M, Chouaid C, Milleron BJ, et al. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. J Clin Oncol. 2010;28 Suppl: Abstr 7507.
34. Petrelli F, Borgonovo K, Cabiddu M, et al. Erlotinib as maintenance therapy in patients with advanced non-small cell lung cancer: a pooled analysis of three randomized trials. Anticancer Drugs. 2011;22:1010-9.
35. Giaccone G, Gallegos Ruiz M, Le Chevalier T, et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res. 2006;12:6049-55.
36. Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy- naïve patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol. 2007;25:760-6.
37. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. N Engl J Med. 2009;361:947-57.
38. Pham DK, Kris MG, Riely GJ, et al. Use of Cigarette-Smoking History to Estimate the Likelihood of Mutations in Epidermal Growth Factor Receptor Gene Exons 19 and 21 in Lung Adenocarcinomas. J Clin Oncol. 2006;24: 1700-4.
39. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomized, phase 3 study. Lancet Oncol. 2011;12:735-42.
40. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer: Biological and Clinical Implications. Cancer Res. 2004;64;8919-23.
41. Matsuo K, Ito H, Yatabe Y, et al. Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese. Cancer Science. 2007;98:96-101.
42. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. Lancet Oncol. 2010;11:121-8.
43. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. N Engl J Med. 2010; 362:2380-8.
44. Taguchi F, Solomon B, Gregorc V, et al. Mass spectrometry to classify nonsmall-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: multicohort cross-institutional study. J Natl Cancer Inst. 2007;99:838-46.
45. Salmon JS, Chen H, Chen S, et al. Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen. J Thorac Oncol. 2009;4: 689-96.
46. Carbone DP, Salmon JS, Billheimer D, et al. VeriStrat classifier for survival and time to progression in non-small-cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer. 2010;69:337-40.
47. Carbone DP, Seymour L, Ding K, et al. Serum Proteomic Prediction of Outcomes in Advanced NSCLC Patients Treated with Erlotinib/Placebo in the NCIC Clinical Trials Group BR.21 Trial. J Thorac Oncol. 2010; 5 Suppl:Abstr 203O.
48. Lazzari C, Spreafico A, Bachi A, et al. Changes in Plasma Mass-Spectral Profile in Course of Treatment of Non-small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. J Thorac Oncol. September 29, 2011. [Epub ahead of print.]
49. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008;359:366-77.
50. Roberts PJ, Stinchcombe TE, Der CJ, et al. Personalized Medicine in Non-Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor-Targeted Therapy? J Clin Oncol. 2010;28:4769-77.